ArticleCureus2026
Correlation Between 1p19q Status and Various Biomarkers in Selected Central Nervous System Tumors.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveH mutations and 1p19q co-deletion are the main biomarkers used in the nomenclature of glial tumors. Detection of 1p19q co-deletion directly diagnoses oligodendroglioma. The primary objective of this study was to evaluate the 1p19q co-deletion status in diffuse gliomas in accordance with the World Health Organization (WHO) integrated classification framework. In addition, we aimed to investigate the presence of 1p19q alterations in other, less frequently encountered glial-derived central nervous system tumors.
methodsWe retrospectively analyzed the biomarker findings obtained from the pathology preparations of 167 cases of glial brain tumors (93M, 74F) operated in the Department of Neurosurgery at Yeditepe University Hospital and whose preparations were investigated in the pathology laboratory between 2019 and 2021. The data was statistically analyzed.
resultsATRX, IDH1, EGFR, GFAP, and OLIG2 positivity were associated with the positivity of 1p19q co-deletion. Our study showed that only 4% of tumors with no O6-methylguanine-DNA methyltransferase (MGMT) methylation showed 1p19q co-deletion positivity. Tumors with low (0-20%) and moderate (21-60%) levels of MGMT methylation showed higher rates of 1p19q co-deletion positivity. However, tumors with high (81-99%) and complete (100%) MGMT methylation had lower rates of 1p19q co-deletion positivity.
conclusionsThe detection of 1p19q co-deletion in other tumors and its peculiar relationship with MGMT methylation made us think of the complexity of tumor biology and how both genetic and epigenetic factors interplay to influence tumor behavior and response to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.